"Nevirapine" - Books

Result Filters

Results: 1 to 20 of 156 books (891 items)

<< First< Prev

Page of 8

Next >Last >>

Select item 48538161.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 44036682.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2026 Jan-.

Top results in this book Table of Contents

Select item 52706023.

NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Study of Mixtures of 3′-Azido-3′-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRNs 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study): NTP GMM 16 [Internet].

Leakey JEA, Allaben WT, Dunnick JK, et al.

Research Triangle Park (NC): National Toxicology Program; 2013 Oct.

Top results in this book Table of Contents

Select item 43295684.

Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment.

O’Donnell A, McParlin C, Robson SC, et al.

Southampton (UK): NIHR Journals Library; 2016 Oct. (Health Technology Assessment, No. 20.74.)

Top results in this book Table of Contents

Select item 42965245.

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition.

Geneva: World Health Organization; 2016.

Top results in this book Table of Contents

Select item 45657286.

Drugs and Lactation Database (LactMed®) [Internet].

Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Top results in this book Table of Contents

Select item 40908227.

Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach: 2010 Version.

Geneva: World Health Organization; 2010.

Top results in this book Table of Contents

Select item 19428088.

Review of the HIVNET 012 Perinatal HIV Prevention Study.

Institute of Medicine (US) Committee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study.

Washington (DC): National Academies Press (US); 2005.

Top results in this book Table of Contents

Select item 31295809.

Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities.

Institute of Medicine (US) Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings; Curran J, Debas H, Arya M, et al., editors.

Washington (DC): National Academies Press (US); 2005.

Top results in this book Table of Contents

Select item 522920210.

Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach [Internet].

Geneva: World Health Organization; 2021 Jul.

Top results in this book Table of Contents

Select item 522256411.

Nutrition and HIV: Epidemiological Evidence to Public Health.

Mehta S, Finkelstein JL, editors.

New York (NY): CRC Press; 2018 May 15.

Top results in this book Table of Contents

Select item 303019612.

Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision.

Geneva: World Health Organization; 2010.

Top results in this book Table of Contents

Select item 583164813.

Medical eligibility criteria for contraceptive use [Internet]. 6th edition.

Geneva: World Health Organization; 2025.

Top results in this book Table of Contents

Select item 141457814.

Antiretroviral Resistance in Clinical Practice.

Geretti AM, editor.

London: Mediscript; 2006.

Top results in this book Table of Contents

Select item 265918215.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 303230016.

Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision.

Geneva: World Health Organization; 2010.

Top results in this book Table of Contents

Select item 408287417.

Manual on Paediatric HIV Care and Treatment for District Hospitals: Addendum to the Pocket Book of Hospital Care of Children.

Geneva: World Health Organization; 2011.

Top results in this book Table of Contents

Select item 165969418.

Disease Control Priorities in Developing Countries. 2nd edition.

Jamison DT, Breman JG, Measham AR, et al., editors.

Washington (DC): The International Bank for Reconstruction and Development / The World Bank; New York: Oxford University Press; 2006.

Top results in this book Table of Contents

Select item 584863819.

WHO updated recommendations on HIV clinical management: recommendations for a public health approach [Internet].

Geneva: World Health Organization; 2025.

Top results in this book Table of Contents

Select item 340129420.

Endotext [Internet].

Feingold KR, Adler RA, Ahmed SF, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

<< First< Prev

Page of 8

Next >Last >>

Supplemental Content

Images search in Bookshelf

NEVIRAPINE

CAS No. 129618-40-2
Chemical Formula: C₁₅H₁₄N₄O Molecular Weight: 266.30
Synonyms: NVP; 11-cyclopropyl-4-methyl-5,11-dihydro-6H- dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one
Trade Name: Viramune^®

Leakey JEA, Allaben WT, Dunnick JK, et al. NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Study of Mixtures of 3′-Azido-3′-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRNs 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study): NTP GMM 16 [Internet]. Research Triangle Park (NC): National Toxicology Program; 2013 Oct.
NEVIRAPINE

CAS No. 129618-40-2
Chemical Formula: C₁₅H₁₄N₄O Molecular Weight: 266.30
Synonyms: NVP; 11-cyclopropyl-4-methyl-5,11-dihydro-6H- dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one
Trade Name: Viramune^®

INTRODUCTION.

Leakey JEA, Allaben WT, Dunnick JK, et al. NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Study of Mixtures of 3′-Azido-3′-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRNs 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study): NTP GMM 16 [Internet]. Research Triangle Park (NC): National Toxicology Program; 2013 Oct.
Figure 12

Binding sites for RT inhibitors. (Top) Structure of HIV-1 RT. The active sites for polymerase and RNase H are shown in gold and brown, respectively, and the nonnucleoside inhibitor binding pocket is shown in blue. (Reprinted from Arnold et al. 1996.) (Bottom, left) Active site and NNRTI-binding region bound to template-primer. The region shown comprises parts of the palm (P) and fingers (f) domains of p66 and the fingers domain of p51. Nucleoside analogs interact with the dNTP-binding site (shown with a docked dTTP substrate). Nonnucleoside inhibitors interact with the adjacent nonnucleoside inhibitor-binding pocket (NNIBP). (Blue spheres) Amino acid substitutions associated with nucleoside analog resistance; (yellow spheres) amino acid substitutions associated with nonnucleoside inhibitor resistance. (Reprinted from Tantillo et al. 1994.) (Bottom, right) The NNRTI-binding region shown with three bound inhibitors: TIBO (green); α-APA (red), and nevirapine (green). (Reprinted from Ding et al. 1995a.) Note that despite their very different structures (Fig. 14), the three inhibitors have a similar conformation when bound.

Pharmacologic Approaches.

Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997.
FIGURE 4

Consolidated Standards of Reporting Trials flow diagram. a, Screening data are missing for three patients. b, A patient was randomised in arm B, even before they attended the clinic, because of a communication error. c, Patient concerned about leg swelling (not an AE) and decided to stop study drug. d, Patient has left the country; patient preference. e, Medication ran out 2 days before final visit; appointment was missed, as patient misunderstood the follow-up schedule; patient lost study medication and failed to inform research team until 48-week follow-up visit. f, Patient moved to London with no forwarding address; did not wish to continue the study because of organisational reasons; because of advice from study team following MRI incidental finding; to enter another clinical trial; eGFR < 60 ml/minute/1.73 m² at screening; on nevirapine. g, Patient developed a cough and wanted to discontinue study medication; taking Rampiril (general practitioner’s orders); switch in ARV; not able to commit to study; eGFR < 60 ml/minute/1.73 m² at baseline; did not meet eligibility criteria; did not return for appointment and did not respond to contacts; decided to become pregnant. h, Patient ran out of study medication; eGFR < 60 ml/minute/1.73 m²; patient ran out of study medication but did not collect extra medication; forgot to take study medication when on holiday abroad; ran out of study medication; ran out of study medication but was unable to come to collect extra medication; did not take study medication as required. i, All three patients had run out of study drug.

Results.

Pushpakom S, Kolamunnage-Dona R, Taylor C, et al. Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Southampton (UK): NIHR Journals Library; 2019 Jul.